Clinical Study Data Flow Maps
Practical guidance for trial sponsors on clinical study data flow mapping in the ICH E6(R3) era.
Why Clinical Data Flow Mapping Matters
The regulatory landscape has shifted.
Under ICH E6(R3), regulators are placing greater emphasis on data architecture, lifecycle transparency, and sponsor oversight. Sponsors are increasingly expected to demonstrate not only where clinical data resides, but how it moves, how it is controlled, and how oversight is exercised across systems, vendors, and functions.
As a result, many sponsors are now being asked to describe or demonstrate their clinical study data flows during GCP inspections, allowing regulatory investigators (inspectors) to assess:
- Data integrity and traceability
- Sponsor oversight across vendors and systems
- Transparency across the full data lifecycle
For many organizations, these questions expose gaps in visibility, ownership, and documentation across increasingly complex clinical data environments.
The goal is not to create a perfect diagram, but to provide a clear, defensible explanation of how study data moves, changes, and is overseen.
Where Trial Sponsors Are Seeking Clarity
Across multiple sponsor discussions and recent educational sessions, several recurring questions continue to surface:
- Do we currently maintain a documented view of how study data flows across vendors and systems?
- How detailed should a data flow map actually be to meet regulatory expectations?
- Who owns the map – clinical operations, data management, or quality?
- How do we trace data transformations across multiple vendors and platforms?
- Where are the biggest risk points in our current data ecosystem?
Clinical study data flow mapping is becoming an increasingly important tool for demonstrating data integrity, traceability, and oversight under ICH E6(R3).
Read the Clinical Leader Article by Just in Time GCP’s Founder and CEO, Donna Dorozinsky:
When Sponsors Can’t Explain How Study Data Flows, Inspection Readiness Breaks Down
How Just in Time GCP Can Help
Just in Time GCP helps trial sponsors translate early data flow mapping efforts into inspection-ready lifecycle documentation through:
- Full-study or multi-study data lifecycle mapping
- Cross-functional R3 alignment workshops
- Vendor oversight process optimization
- TMF-integrated data traceability frameworks
- Inspection readiness preparation specific to data lifecycle controls
- Technical + operational harmonization across systems
A Practical Starting Point for Sponsors
For sponsors looking to explore this topic further, Just in Time GCP has captured key insights from industry discussions and developed a high-level starting point.
This resource is designed to help teams frame the right questions and boundaries for clinical study data flow mapping. However, it is intentionally not exhaustive. Rather, it supports early scoping conversations and highlights where additional structure or expertise may be required. It is designed to support informed decision-making, not to standardize or prescribe implementation.
